Vast Clinical Research LLC — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$147,836	26
2024	Research	$126,906	16

Breakdown

Who paid Research payments · program years 2024–2025

Sanofi US Services Inc. $158,813 14 payments
Janssen Research & Development, LLC $58,854 7 payments
Tolmar, Inc. $21,126 12 payments
Indivior Inc. $18,650 7 payments
Novartis Pharmaceuticals Corporation $17,300 2 payments

Studies the money was for Research payments · program years 2024–2025

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma $79,734 5 payments
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $53,795 5 payments
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa $43,121 4 payments
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD $35,958 5 payments
A Phase IV Longitudinal Study of SUBLOCADE (SUBUTEX Prolonged Release) Clinical Outcomes in Adults With Opioid Use Disorder (Opioid Dependence) $18,650 7 payments
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months $14,350 6 payments
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease $11,500 1 payment
Tol-Clar-20024 $6,776 6 payments
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi $5,800 1 payment
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms $5,059 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.